Nevertheless, one promising antigen for CAR-based cell therapy is CD33, which is expressed on leukemic blasts and leukemia-inducing cells in up to 88% of AML patients9,10, and preclinical results have demonstrated anti-AML activity of CD33-specific CAR-T cells11,12. The gene discussed is CD33; the disease is acute myeloid leukemia.